A detection antibody, application and detection method of anti-vegfr-2 monoclonal antibody

Abstract

The invention provides a detection antibody, application and detection method of an anti-VEGFR-2 monoclonal antibody. The detection antibody includes a heavy chain variable region and a light chain variable region, and the amino acid sequence of the heavy chain variable region is selected from SEQ. ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8; the amino acid sequence of the light chain variable region is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 or SEQ ID NO:12. The present invention has screened a detection antibody against anti-VEGFR-2 monoclonal antibody, which can quickly, sensitively and accurately detect the drug concentration of anti-VEGFR-2 monoclonal antibody in body fluids, in order to assist the detection of anti-VEGFR-2 The pharmacology and pharmacokinetic analysis of monoclonal antibody clinical diagnosis and clinical trials provide reliable research methods.

Description

technical field [0001] The invention relates to the technical field of bioengineering, in particular to a detection antibody, application and detection method of an anti-VEGFR-2 monoclonal antibody. Background technique [0002] The dependence of tumor growth on the formation of new blood vessels has been thoroughly studied in tumor biology. Neoangiogenesis refers to the process of budding new blood vessels from pre-existing capillaries. This process is stimulated and regulated by a variety of factors, including basic fibroblast growth factor (BFGF), vascular endothelial growth factor (vascular endothelial growth factor, VEGF), platelet-derived growth factor (platelet -derived growth factor, PDGF), angiopoietin-1 (angiopoietin-1), hepatocyte growth factor (hepatocyte growth factor, HGF), transforming growth factor-β (transforming growth factor-β, TGF-β), interleukin Prime 6 (interleukin-6, IL-6) and so on. Among them, VEGF is the most powerful and specific factor to stimu...

AI Technical Summary

Problems solved by technology

[0004] At present, due to the key role of the VEGF / VEGFR2 signaling pathway in the occurrence and development of tumors, more and more biopharmaceutical companies are investing in the research and development of anti-VEGFR-2 monoclonal antibodies. There are many patents published at present. For example, the US patent application number is US10 / 506997, the patent name is: Human antibodies specific to KDR and uses thereof; Chinese patent CN201210533178.3, the patent name is: human anti-human vascular endothelial growth factor antibody and its application; Chinese patent CN 201710130518.0, the patent name is: An improved anti-VEGFR-2 monoclonal antibody, etc., the above-mentioned patents are all aimed at the research and development of anti-VEGFR-2 monoclonal antibody, and there is no research specifically on the drug concentration detection scheme of a certain anti-VEGFR-2 monoclonal antibody, which has great impact on The antibody is inconvenient in the pharmacology and pharmacokinetic analysis of clinical diagnosis and clinical trials. Therefore, the present invention provides an improved anti-VEGFR-2 monoclonal antibody (light chain variable region of the antibody) in the existing patent CN201710130518.0 The amino acid sequence comprises any one of SEQ NO:1, SEQ NO:2 or SEQ NO:3; on the basis of the amino acid sequence of the heavy chain variable region being SEQ NO:4), a special method for detecting the Detecting antibody for drug concentration of anti-VEGFR-2 monoclonal antibody in patent

Images